Journal of Clinical Pathways
March 26, 2025
"The FDA's recent update stresses the importance of oncology care teams being aware of the risks of DPD deficiency, informing patients about these risks—including serious or life-threatening toxicities—before treatment, and discussing testing for the deficiency with their patients." - Houda Hachad, PharmD, M.Res, Vice President Clinical Operations at Aranscia.
Click here to read more in the Journal of Clinical Pathways.